

Substitute for Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 033388-589
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/500932
INTERNATIONAL APPLICATION NO. PCT/US03/00377	INTERNATIONAL FILING DATE 08 January 2003 (08.01.2003)	PRIORITY DATE CLAIMED 09 January 2002 (09.01.2002)	
TITLE OF INVENTION EFFICIENT LIPOSOMAL ENCAPSULATION			
APPLICANT(S) FOR DO/EO/US LI, Xingong; TONG, Shangguan; POLOZOVA, Alla; MEERS, Paul, R.; PERKINS, Walter, R.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission to items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11 to 21 below concern document(s) or information included:			
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: <u>Application Data Sheet; General Authorization For Petitions For Extensions of Time and Payment of Fees; PCT/IPEA/408; PCT/IPEA/409; and PCT/ISA/210.</u> 21. <input checked="" type="checkbox"/> Applicant(s) requests that the published application include the following assignment information: <u>ELAN PHARMACEUTICALS, INC., San Francisco, California, US</u> 			

U.S. APPLICATION NO. 10/500932 <small>(If known, see 37 CFR 1.55)</small>	INTERNATIONAL APPLICATION NO. PCT/US03/00377	ATTORNEY'S DOCKET NUMBER 033388-589
---	--	---

22. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):
 Neither international preliminary examination fee (37 CFR 1.482)
 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
 and International Search Report not prepared by the EPO or JPO \$1,080.00 (1611)

International preliminary examination fee (37 CFR 1.482) not paid to
 USPTO but International Search Report prepared by the EPO or JPO \$920.00 (1613)

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
 but International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00 (1610)

International preliminary examination fee (37 CFR 1.482) paid to USPTO
 but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00 (1609)

International preliminary examination fee (37 CFR 1.482) paid to USPTO
 and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 (1612)

ENTER APPROPRIATE BASIC FEE AMOUNT =	\$ 100.00	
Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30		

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total Claims	106	-20 = 86	X \$18.00 (1615)	\$ 1,548.00	
Independent Claims	6	-3 = 3	X \$86.00 (1614)	\$ 258.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$290.00 (1616)	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =				\$ 1,906.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	\$ 0.00
SUBTOTAL =				\$ 1,906.00	
Processing fee of \$130.00 (1618) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					\$ 0.00
TOTAL NATIONAL FEE =				\$ 1,906.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +					\$ 0.00
TOTAL FEES ENCLOSED =				\$ 1,906.00	
				Amount to be refunded :	
				charged :	

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. **02-4800** in the amount of _____ to cover the above fees. A
 duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
 Deposit Account No. **02-4800**. A duplicate copy of this sheet is enclosed.

d. ☒ Charge **\$ 1,906.00** to credit card. Form PTO-2038 is attached.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a)
 or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Burns, Doane, Swecker & Mathis, L.L.P.
 P.O. Box 1404
 Alexandria, Virginia 22313-1404
 (703) 836-6620



 SIGNATURE

 NAME
 Teresa Stanek Rea

 30,427
 REGISTRATION NO.

 July 8, 2004
 DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/500932

In re Patent Application of

Xingong Li et al.

Application No.:

Filing Date: July 8, 2004

Title: EFFICIENT LIPOSOMAL ENCAPSULATION

Group Art Unit:

Examiner:

Confirmation No.:

**GENERAL AUTHORIZATION FOR PETITIONS
FOR EXTENSIONS OF TIME AND PAYMENT OF FEES**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.136(a)(3), the U.S. Patent and Trademark Office is hereby provided with a general authorization to treat any concurrent or future reply requiring a petition for an extension of time for its timely submission as containing a request therefor for the appropriate length of time.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By

Teresa Stanek Rea
Registration No. 30,427

Date: July 8, 2004